Annual Review of Cancer Biology
Overview
Annual Review of Cancer Biology is a scientific journal, published by Annual Reviews since 2017 in English. The journal's country of origin is United States.
Details
Details
Abbr.
Annu Rev Cancer Biol
Publisher
Annual Reviews
Start
2017
End
Continuing
Frequency
Annual
e-ISSN
2472-3428
Country
United States
Language
English
Metrics
Metrics
h-index / Ranks: 9376
36
SJR / Ranks: 403
3766
CiteScore / Ranks: 313
21.00
Recent Articles
1.
Reczek C, Chandel N
Annu Rev Cancer Biol
. 2025 Mar;
1:79-98.
PMID: 40034143
Reactive oxygen species (ROS), now appreciated for their cellular signaling capabilities, have a dual role in cancer. On the one hand, ROS can promote protumorigenic signaling, facilitating cancer cell proliferation,...
2.
Scheiter A, Lu L, Gao L, Feng G
Annu Rev Cancer Biol
. 2025 Feb;
8(1):15-33.
PMID: 39959686
The non-receptor tyrosine phosphatase SHP2 has been at the center of cell signaling research for three decades. SHP2 is required to fully activate the RTK-RAS-ERK cascade, although the underlying mechanisms...
3.
Limoli C, Vozenin M
Annu Rev Cancer Biol
. 2024 Oct;
7:1-21.
PMID: 39421564
Ultrahigh-dose rate FLASH radiotherapy (FLASH-RT) is a potentially paradigm-shifting treatment modality that holds the promise of expanding the therapeutic index for nearly any cancer. At the heart of this exciting...
4.
Meermeier E, Bergsagel P, Chesi M
Annu Rev Cancer Biol
. 2024 Oct;
8:351-371.
PMID: 39364307
Recent therapeutic advances have significantly improved the outcome for patients with multiple myeloma (MM). The backbone of successful standard therapy is the combination of Ikaros degraders, glucocorticoids, and proteasome inhibitors...
5.
Murciano-Goroff Y, Uppal M, Chen M, Harada G, Schram A
Annu Rev Cancer Biol
. 2024 Jun;
8(1):59-80.
PMID: 38938274
Large-scale tumor molecular profiling has revealed that diverse cancer histologies are driven by common pathways with unifying biomarkers that can be exploited therapeutically. Disease-agnostic basket trials have been increasingly utilized...
6.
Bonsor D, Simanshu D
Annu Rev Cancer Biol
. 2024 Jun;
8:97-113.
PMID: 38882927
Mutations in RAS proteins play a pivotal role in the development of human cancers, driving persistent RAF activation and deregulating the Mitogen-Activated Protein Kinase (MAPK) signaling pathway. While progress has...
7.
Straehla J, Reardon D, Wen P, Agar N
Annu Rev Cancer Biol
. 2024 Feb;
7:265-289.
PMID: 38323268
The blood-brain barrier is critically important for the treatment of both primary and metastatic cancers of the central nervous system (CNS). Clinical outcomes for patients with primary CNS tumors are...
8.
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor-Based Cellular Therapy
Martinov T, Greenberg P
Annu Rev Cancer Biol
. 2023 Sep;
7(1):331-351.
PMID: 37655310
T cell reactivity to tumor-specific neoantigens can drive endogenous and therapeutically induced antitumor immunity. However, most tumor-specific neoantigens are unique to each patient (private) and targeting them requires personalized therapy....
9.
Dougan M, Dranoff G, Dougan S
Annu Rev Cancer Biol
. 2023 Aug;
3:55-75.
PMID: 37539076
Blocking antibodies to the immune checkpoint receptors or their ligands have revolutionized the treatment of diverse malignancies. Many tumors are recognized by adaptive immunity, but these adaptive responses can be...
10.
Connolly K, Fitzgerald B, Damo M, Joshi N
Annu Rev Cancer Biol
. 2023 Mar;
6(1):269-291.
PMID: 36875867
Mouse models for the study of cancer immunology provide excellent systems in which to test biological mechanisms of the immune response against cancer. Historically, these models have been designed to...